MEDI2070 Shows Clinical Benefit in Crohn’s Disease

MEDI2070 Shows Clinical Benefit in Crohn’s Disease
During Digestive Disease Week (May 16-19) in Washington, D.C., Bruce E. Sands, MD, of the Division of Gastroenterology at the Icahn School of Medicine in Mount Sinai, New York presented results where a new monoclonal antibody called MEDI2070 (MedImmune) led to improvements in clinical outcomes in 121 patients with Crohn’s disease. Dr. Sands and colleagues investigated in a double blind trial the effects of the drug that targets IL-23 by selectively binding to its p19 subunit. Patients taking part in the study were all adults with a Crohn’s Disease Activity Index (CDAI) score of more than 220 and 450 or less, had active inflammation, and who had failed or were intolerant to anti-TNF therapy. “This was a fairly ill population with a mean CDAI score above 300,” Sands said in a recent news release. Many patients had been exposed to adalimumab and infliximab prior to study entry. Patients were assigned to receive MEDI2070 700 mg IV or placebo at weeks 0 and 4 and then followed through week 12. Patient stratification was conducted according to the number of anti-TNF agents they previously had. A total of 59 patients were assigned to receive the active
Subscribe or to access all post and page content.